| REGISTERED NUMBER: |
| UNAUDITED FINANCIAL STATEMENTS |
| FOR THE YEAR ENDED 31 DECEMBER 2025 |
| FOR |
| NANOSYRINX LTD |
| REGISTERED NUMBER: |
| UNAUDITED FINANCIAL STATEMENTS |
| FOR THE YEAR ENDED 31 DECEMBER 2025 |
| FOR |
| NANOSYRINX LTD |
| NANOSYRINX LTD (REGISTERED NUMBER: 11595354) |
| CONTENTS OF THE FINANCIAL STATEMENTS |
| for the year ended 31 December 2025 |
| Page |
| Company Information | 1 |
| Abridged Balance Sheet | 2 |
| Notes to the Financial Statements | 4 |
| NANOSYRINX LTD |
| COMPANY INFORMATION |
| for the year ended 31 December 2025 |
| DIRECTORS: |
| REGISTERED OFFICE: |
| REGISTERED NUMBER: |
| BANKERS: |
| London |
| NANOSYRINX LTD (REGISTERED NUMBER: 11595354) |
| ABRIDGED BALANCE SHEET |
| 31 December 2025 |
| 2025 | 2024 |
| as restated |
| Notes | £ | £ | £ | £ |
| FIXED ASSETS |
| Intangible assets | 4 |
| Tangible assets | 5 |
| CURRENT ASSETS |
| Debtors |
| Cash at bank |
| CREDITORS |
| Amounts falling due within one year |
| NET CURRENT ASSETS |
| TOTAL ASSETS LESS CURRENT LIABILITIES |
| CAPITAL AND RESERVES |
| Called up share capital | 7 |
| Share premium | 8 |
| Other reserves | 8 |
| Retained earnings | 8 | ( |
) | ( |
) |
| SHAREHOLDERS' FUNDS |
| The directors acknowledge their responsibilities for: |
| (a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and |
| (b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company. |
| NANOSYRINX LTD (REGISTERED NUMBER: 11595354) |
| ABRIDGED BALANCE SHEET - continued |
| 31 December 2025 |
| The financial statements were approved by the Board of Directors and authorised for issue on |
| NANOSYRINX LTD (REGISTERED NUMBER: 11595354) |
| NOTES TO THE FINANCIAL STATEMENTS |
| for the year ended 31 December 2025 |
| 1. | STATUTORY INFORMATION |
| NanoSyrinx Ltd is a |
| 2. | ACCOUNTING POLICIES |
| Basis of preparing the financial statements |
| These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. |
| The financial statements are presented in sterling which is the functional currency of the company and is rounded to the nearest £1. |
| Intangible assets |
| Patents are being amortised ay 6.5% per annum. |
| Tangible fixed assets |
| Laboratory equipment | - |
| Fixtures and fittings | - |
| Computer equipment | - |
| Taxation |
| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
| Current or deferred taxation assets and liabilities are not discounted. |
| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
| Deferred tax |
| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. |
| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference. |
| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
| Hire purchase and leasing commitments |
| Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease. |
| Pension costs and other post-retirement benefits |
| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate. |
| NANOSYRINX LTD (REGISTERED NUMBER: 11595354) |
| NOTES TO THE FINANCIAL STATEMENTS - continued |
| for the year ended 31 December 2025 |
| 2. | ACCOUNTING POLICIES - continued |
| Share based payments |
| Where share options are awarded, the fair value of the options at the date of grant is charged to the Income Statement over the vesting period. The total amount to be expensed over the vesting period is determined by reference to the fair value of the options granted at the date of the grant, excluding the impact of any non-market vesting conditions. |
| At each balance sheet date the company revises its estimates of the number of options that are expected to vest. It recognises the impact of the revision to the original estimates, if any, in the Income Statement. The credit entry is taken to reserves because the share options are equity-settled. |
| Where equity instruments are granted to persons other than employees, the Income Statement is charged with the fair value of goods and services received. |
| The share options are exercisable on the Ordinary share capital of the company. |
| 3. | EMPLOYEES AND DIRECTORS |
| The average number of employees during the year was |
| 4. | INTANGIBLE FIXED ASSETS |
| Totals |
| £ |
| COST |
| At 1 January 2025 |
| Additions |
| At 31 December 2025 |
| AMORTISATION |
| At 1 January 2025 |
| Amortisation for year |
| At 31 December 2025 |
| NET BOOK VALUE |
| At 31 December 2025 |
| At 31 December 2024 |
| NANOSYRINX LTD (REGISTERED NUMBER: 11595354) |
| NOTES TO THE FINANCIAL STATEMENTS - continued |
| for the year ended 31 December 2025 |
| 5. | TANGIBLE FIXED ASSETS |
| Totals |
| £ |
| COST |
| At 1 January 2025 |
| Additions |
| At 31 December 2025 |
| DEPRECIATION |
| At 1 January 2025 |
| Charge for year |
| At 31 December 2025 |
| NET BOOK VALUE |
| At 31 December 2025 |
| At 31 December 2024 |
| 6. | LEASING AGREEMENTS |
| Minimum lease payments under non-cancellable operating leases fall due as follows: |
| 2025 | 2024 |
| as restated |
| £ | £ |
| Within one year |
| 7. | CALLED UP SHARE CAPITAL |
| Allotted, issued and fully paid: |
| Number: | Class: | Nominal | 2025 | 2024 |
| value: | as restated |
| £ | £ |
| Ordinary | 0.000001p | 2 | 2 |
| Seed Ordinary | 0.000001p | 8 | 8 |
| 10 | 10 |
| The following fully paid shares were allotted during the year at a premium as shown below: |
| 12,400 Ordinary shares of 0.000001p each at 0.000099p per share |
| 787,036 Seed Ordinary shares of 0.000001p each at 215.999999p per share |
| NANOSYRINX LTD (REGISTERED NUMBER: 11595354) |
| NOTES TO THE FINANCIAL STATEMENTS - continued |
| for the year ended 31 December 2025 |
| 8. | RESERVES |
| Retained | Share | Other |
| earnings | premium | reserves | Totals |
| £ | £ | £ | £ |
| At 1 January 2025 | ( |
) | 9,996,657 |
| Deficit for the year | ( |
) | ( |
) |
| Cash share issue | - | 1,681,157 | - | 1,681,157 |
| Share based payments | - | - | 462,827 | 462,827 |
| At 31 December 2025 | ( |
) | 7,602,378 |
| 9. | PENSION COMMITMENTS |
| The company operates a defined contribution pension scheme in respect of the directors and employees. The scheme and its assets are held by independent managers. The pension charge represents contributions due from the company and amounted to £186,758 (2024 - £114,476). At the year end there was a balance outstanding amounting to £51,899 (2024 - £24,806). |
| 10. | SHARE-BASED PAYMENT TRANSACTIONS |
| Certain individuals participate in an equity compensation plan. The plan is administered by the company's Board of Directors, which has the authority to determine which individuals are granted stock option awards. Upon exercise, the option awards are settled in shares and cannot be settled in cash. The cost of this scheme are disclosed in the preceding notes and have been made in order to match relevant expenditure and changes in equity. |
| A summary of stock option activity for company employees for the period ended 31 December 2025 is as follows: |
Details | Number of Options | Weighted Ave. Exercise Price |
| Outstanding at 1 January 2025 | 1,262,020 | £0.023 |
| Granted during the year | 181,800 | £0.000001 |
| Exercised during the year | (12,400 | ) | £0.0001 |
| Forfeited during the year | (17,900 | ) | £0.000085 |
| Outstanding at 31 December 2025 | 1,413,520 | £0.0205 |
| 11. | CONTROLLING PARTY |
| The directors do not consider there to be a single controlling or ultimate controlling party. |